Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service

Abstract

BackgroundSingle gene tests to predict whether cancers respond to specific targeted therapies are performed increasingly often. Advances in sequencing technology, collectively referred to as next generation sequencing (NGS), mean the entire cancer genome or parts of it can now be sequenced at speed with increased depth and sensitivity. However, translation of NGS into routine cancer care has been slow. Healthcare stakeholders are unclear about the clinical utility of NGS and are concerned it could be an expensive addition to cancer diagnostics, rather than an affordable alternative to single gene testing.Methods and findingsWe validated a 46-gene hotspot cancer panel assay allowing multiple gene testing from small diagnostic biopsies. From 1 January 2013 to 31 December 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcinoma, and melanoma) were sequenced in the context of the UK National Health Service from 351 consecutively submitted prospective cases for which treating clinicians thought the patient had potential to benefit from more extensive genetic analysis. Following histological assessment, tumour-rich regions of formalin-fixed paraffin-embedded (FFPE) sections underwent macrodissection, DNA extraction, NGS, and analysis using a pipeline centred on Torrent Suite software. With a median turnaround time of seven working days, an integrated clinical report was produced indicating the variants detected, including those with potential diagnostic, prognostic, therapeutic, or clinical trial entry implications. Accompanying phenotypic data were collected, and a detailed cost analysis of the panel compared with single gene testing was undertaken to assess affordability for routine patient care.Panel sequencing was successful for 97% (342/351) of tumour samples in the prospective cohort and showed 100% concordance with known mutations (detected using cobas assays). At least one mutation was identified in 87% (296/342) of tumours. A locally actionable mutation (i.e., available targeted treatment or clinical trial) was identified in 122/351 patients (35%). Forty patients received targeted treatment, in 22/40 (55%) cases solely due to use of the panel. Examination of published data on the potential efficacy of targeted therapies showed theoretically actionable mutations (i.e., mutations for which targeted treatment was potentially appropriate) in 66% (71/107) and 39% (41/105) of melanoma and NSCLC patients, respectively. At a cost of £339 (US$449) per patient, the panel was less expensive locally than performing more than two or three single gene tests.Study limitations include the use of FFPE samples, which do not always provide high-quality DNA, and the use of “real world” data: submission of cases for sequencing did not always follow clinical guidelines, meaning that when mutations were detected, patients were not always eligible for targeted treatments on clinical grounds.ConclusionsThis study demonstrates that more extensive tumour sequencing can identify mutations that cou...

Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident

“…IR, ionizing radiation; MPN, myeloproliferative neoplasms splenomegaly (218 mm by ultrasound), and hepatomegaly (191 mm by ultrasound) and was erythrocyte-transfusion dependent. Previously the same ATM S1691R variant was reported in an Ataxia-Telangiectasia family 57 and in patients with chronic lymphocytic leukemia, including 1 case with LOH at D11S2179, 58,59 breast cancer, [60][61][62] and melanoma, 63 but not in MPN patients.…”

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

“…After the study halt, simultaneously running phase I studies of VSV-EBOV included arthralgia/arthritis as a solicited adverse event, but while transient arthralgia was likewise reported, the high frequency of arthritis cases was not observed to the same extent. [28][29][30][31]41 Finally, arthritis frequency was assessed in a large placebocontrolled phase III trial. Here, the incidence of arthritis or joint swelling was 4.9% in a study population of 1050 individuals.…”

“…31 Notably, children (6-12 years of age) and, less pronouncedly, adolescents were found to have higher viremia and shedding frequency than adults when vaccinated with 2 × 10 7 PFU of VSV-EBOV, raising the question whether lower vaccine doses might be required in pediatric populations. 41…”

“…Despite the observed aforementioned higher viremia in a total of 40 pediatric individuals by Agnandji and colleagues, the vaccine had a comparable safety and immunogenicity profile to that of adults receiving the same dose. 41 A subsequent phase III trial as well as vaccine usage under expanded access showed an acceptable safety profile in over 500 vaccinated children aged 6-17. 33,43 Unpublished and ongoing trials are now also including children aged 1 year and above (Médecins Sans Frontières (MSF) (NCT03161366) and PREVAC trials) and will hopefully provide more data on safety and efficacy of VSV-EBOV in the pediatric population.…”

Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness

“…On average, the cost of targeted gene panel sequencing per sample was found to be US $1609 (range: US$488-US$3443). Cost of sequencing is generally lower if it is performed in-house [25][26][27] compared to outsourcing to a service provider. [28][29][30]32 Two articles reported cost of WES and RNAseq.…”